Recent Updates
Recently added Catalysts

DFD-29 Fasting

Phase 1

Pharmacokinetics | Small molecule | Other |Journey Medical Corporation|Last Updated: Mar 2, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05452785A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human SubjectsPHASE1 COMPLETED 24May 7, 2022May 25, 2022Mar 2, 20231 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Peak Plasma Concentration (Cmax) of DFD-29 compared to Solodyn(R)
Time '0' to '72' hours after a single dose treatment

Peak plasma concentration (Cmax) - the 90% CI for the ratio of Geometric Least Square Means for the ln-transformed parameter Cmax will be compared between the three treatments.

Area under the Curve (AUC0-inf) of DFD-29 compared to Solodyn(R)
Time '0' to '72' hours after a single dose treatment

Area under the Curve (AUC0-inf) - the 90% CI for the ratio of Geometric Least Square Means for the ln-transformed parameter AUC0-inf will be compared between the three treatments.

Secondary Endpoints
Number of participants with treatment-related adverse events (AE)
Before and up to 14 days after the last dose study treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
DFD-29 under fasting conditionEXPERIMENTALIn each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
DFD-29 after high-fat mealEXPERIMENTALIn each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
Solodyn under fasting conditionACTIVE_COMPARATORIn each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast
Interventions
NameTypeDescription
DFD-29 (Minocycline) FastingDRUGIn each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
DFD-29 (Minocycline) FedDRUGIn each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
Solodyn (Minocycline) FastingDRUGIn each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1\. Provision of signed and dated Informed Consent Form (ICF) 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Healthy adult male or postmenopausal females 4. If female, meets one of the following criteria: 1. Physiolog...

Countries:Canada
Unlock Eligibility Criteria